Impact of waist circumference reduction on cardiovascular risk in treated obese subjects;Impacto de la disminución del perímetro de la cintura en el riesgo cardiovascular de pacientes obesos sujetos a tratamiento

Cirugia y Cirujanos

Volumn 79, Issue 2, 2011, Pages 175-181

  Fanghänel, Guillermo ^a   Sánchez Reyes, Leticia ^a   Félix García, Luis ^b   Violante Ortiz, Rafael ^c   Campos Franco, Enrique ^a   Alcocer, Luis Antonio ^d  

^a Dr Eduardo Liceaga   (Mexico)

^b PEMEX   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d SECRETARÍA DE SALUD   (Mexico)

Author keywords

Cardiovascular risk; Framingham risk; Obesity; Waist circumference

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CYCLOBUTANE DERIVATIVE; LACTONE; LIPID; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DIET THERAPY; DIRECTIVE COUNSELING; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOTOR ACTIVITY; MULTIMODALITY CANCER THERAPY; OBESITY; PSYCHOLOGICAL ASPECT; RISK; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; COMORBIDITY; CYCLOBUTANES; DIABETES MELLITUS; DIRECTIVE COUNSELING; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; LACTONES; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOTOR ACTIVITY; OBESITY; RISK; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 79959345674     PISSN: 00097411     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Barquera S, Campos-Nonato I, Hernández-Barrera L, Flores M, Durazo- Arvizu R, Rivera J. Obesity and central adiposity in Mexican adults: results from the Mexican Health and Nutrition Survey 2006. Salud Publica Mex 2009;51(suppl 4):S540-S550.
2. National Institutes of Health. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998;suppl 2:51S-209S.
3. Kuczmarski RJ, Fegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Survey, 1960 to 1991. JAMA 1994;272:205- 211. (Pubitemid 24209082)
4. Fegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998;22:39-47. (Pubitemid 28036587)
5. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999;282:1519-1522. (Pubitemid 29504044)
6. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-1727.
7. Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease: AHA Nutrition Committee. Circulation 1998;97:2099-2100. (Pubitemid 28262114)
8. Yusuf S, Hawken S, Ounpuu S. On behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet 2004;364:937-952. (Pubitemid 39208455)
9. Grundy SM, Cleeman JI, Daniels SR, Donato A, Eckel H, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
10. Berber A, Gómez-Santos R, Fanghänel G, Sánchez-Reyes L. Anthropometric indexes in the prediction of type 2 diabetes mellitus, hypertension and dyslipidaemia in a Mexican population. Int J Obes Relat Metab Disord 2001;25:1794-1799. (Pubitemid 33131920)
11. Sánchez C, Velázquez MO, Berber A, Lara EA, Tapia CR, James PT. Anthropometric cutoff points for predicting chronic diseases in the Mexican national health survey 2000. Obesity Res 2003;11:442- 451. (Pubitemid 41151634)
12. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, et al. Adult treatment panel III 2001 but not International Diabetes Federation 2005. Criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 2006;29:901-907.
13. Lee S, Bacha F, Gungor N, Arslanian SA. Waist circumference is an independent predictor of insulin resistance in black and white youths. J Pediatr 2006;148:188-194. (Pubitemid 43286759)
14. Palaniappan L, Carnethon M, Wang Y, Hanley A, Fortmann S, Haffner S, et al. Predictors of the Incident Metabolic Syndrome in Adults The Insulin Resistance Atherosclerosis Study. Diabetes Care 2004;27:788-793. (Pubitemid 38280551)
15. Seidell JC, Bjömtrop P, Sjöstrom L, Sannerstedt R, Krotkiewski M, Kvist H. Regional distribution of muscle and fat mass in men-new insight into the risk of abdominal obesity using computed tomography. Int J Obesity 1989;13:289-303. (Pubitemid 19156402)
16. Haffner SM, Despres JP, Balkau B, Deanfield JE, Barter P, Bassand JP, et al. Waist circumference and body mass index are both independently associated with cardiovascular disease: The International Day for the Evaluation of Abdominal Obesity (IDEA) survey. J Am Coll Cardiol 2006;47(4 Suppl A):358A. [Abstract 842-846].
17. Velásquez O, Rosas M, Lara A, Pastelín G, Attié F, Tapia R. Prevalencia e interrelación de enfermedades crónicas no trasmisibles y factores de riesgo cardiovascular en México: ENSA 2000. Arch Cardiol Mex 2003;73:62-77. (Pubitemid 36503014)
18. Velásquez O, Rosas M, Lara AE, Pastelín G; Grupo ENSA 2000. Hipertensión arterial en México: Resultados de ENSA 2000. Arch Cardiol Mex 2002;72:71-84.
19. Fanghänel G, Padilla J, Sánchez-Reyes L, Torres E, Cortinas L, Espinosa- Campos J. Prevalence of coronary artery risk factors in workers at the General Hospital General of Mexico of the Ministry of Health. Endocr Practice 1997;3:313-319.
20. Fanghänel G, Sánchez-Reyes L, Arellano S, Valdez E, Chavira J, Rascón-Pacheco RA. The prevalence of risk factors for coronary disease in workers of the Hospital General de Mexico. Salud Publica Mex 1997;39:427-432. (Pubitemid 27512549)
21. Fanghänel G, Cortinas L, Sánchez-RL, Berber A. A clinical trial of the use of Sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord 2000; 24; 144-150. (Pubitemid 30107561)
22. Fanghänel G, Cortinas L, Sánchez-Reyes L. Berber A. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: six months after treatment cross-over. Int J Obes 2001;25:741-747. (Pubitemid 32417646)
23. Fanghänel G, Sánchez-Reyes L, Berber A. Safety and efficacy of Sibutramine in overweight Hispanic patients with hypertension. Adv Ther 2003;20:101-113. (Pubitemid 36667540)
24. Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez RL, Campos FE, Berber A. Use of sibutramine in overweight and obese Hispanic patients suffering type 2 diabetes mellitus. A 12-month, double blind, randomized, placebo-controlled clinical trial. Clin Ther 2004;26:1427-1435. (Pubitemid 39572156)
25. Lena VG. Obesity, the metabolic syndrome and cardiovascular disease. Am Heart J 2001;142:1109-1116.
26. Poinier P, Giles TD, Bray G, Hong Y, Stem J, Pi-Sunyer X, et al. Obesity and cardiovascular disease: pathophysiology, evaluation and effect of weight loss. Circulation 2006;113:898-918.
27. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005;149:54-60. (Pubitemid 40126490)